Osmol Therapeutics, a privately held biopharmaceutical company focused on developing a treatment to prevent chemotherapy-induced peripheral neuropathy (CIPN), today announced that Teresa Bitetti, President of the Global Oncology Business Unit at Takeda Pharmaceutical Company Ltd., has joined the Board of Directors of Osmol Therapeutics.
Osmol Therapeutics today announced that it has initiated Investigational New Drug (IND) enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN). A phase 1 clinical study is projected to begin in 2022. There are currently no Food and Drug Administration (FDA) approved therapies for the prevention or treatment of CIPN, a debilitating condition resulting from the off-target toxicity of many chemotherapy treatments.
Bob Linke, CEO of Osmol, was interviewed for the CEO Leadership Series sponsored by Ashton-Tweed, a life sciences executive search firm Mr. Linke discusses OSM-0205, the company’s ground-breaking CIPN treatment and managing a virtual team during the COVID-19 pandemic.
Osmol Therapeutics today announced that it has initiated Investigational New Drug (IND) enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN). A phase 1 clinical study is projected to begin in 2022. There are currently no Food and Drug Administration (FDA) approved therapies for the prevention or treatment of CIPN, a debilitating condition resulting from the off-target toxicity of many chemotherapy treatments.
Osmol Therapeutics Inc., of New Haven, Conn., said it initiated IND-enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN). A phase I study is projected by the company to begin in 2022.